Oculis (NASDAQ:OCS) Lowered to Sell Rating by Wall Street Zen

Key Points

• Oculis (NASDAQ:OCS) has been downgraded from a "hold" rating to a "sell" rating by Wall Street Zen, indicating a shift in analyst sentiment.
• Despite the downgrade, four analysts have rated the stock with a Buy rating and the average price target remains at $35.75.
• Oculis reported a loss of ($0.59) EPS for the latest quarter, missing consensus estimates, while showing a significant negative return on equity of 90.31%.

Wall Street Zen lowered shares of Oculis (NASDAQ:OCS - Free Report) from a hold rating to a sell rating in a report released on Sunday.

Several other equities research analysts also recently weighed in on OCS. Needham & Company LLC began coverage on shares of Oculis in a research note on Wednesday, August 27th. They set a "buy" rating and a $36.00 target price for the company. HC Wainwright increased their target price on shares of Oculis from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday, August 22nd. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $35.75.

Oculis Stock Performance

NASDAQ OCS traded up $0.27 during trading hours on Friday, hitting $18.00. The company had a trading volume of 14,025 shares, compared to its average volume of 41,633. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.55 and a current ratio of 4.55. Oculis has a 1-year low of $11.90 and a 1-year high of $23.08. The company has a market cap of $785.88 million, a PE ratio of -6.74 and a beta of 0.27. The business has a 50 day moving average of $17.54 and a 200-day moving average of $18.15.

Oculis (NASDAQ:OCS - Get Free Report) last announced its earnings results on Thursday, August 21st. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.06). Oculis had a negative return on equity of 90.31% and a negative net margin of 13,958.12%.The business had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.14 million. As a group, equities research analysts expect that Oculis will post -2.09 EPS for the current year.

Institutional Investors Weigh In On Oculis

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Pivotal bioVenture Partners Investment Advisor LLC lifted its position in shares of Oculis by 32.4% during the 1st quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company's stock valued at $43,784,000 after acquiring an additional 563,078 shares during the period. Aberdeen Group plc lifted its position in shares of Oculis by 24.1% during the 1st quarter. Aberdeen Group plc now owns 1,253,119 shares of the company's stock valued at $23,847,000 after acquiring an additional 243,695 shares during the period. SR One Capital Management LP acquired a new stake in shares of Oculis during the 1st quarter valued at approximately $6,137,000. Alyeska Investment Group L.P. acquired a new stake in shares of Oculis during the 1st quarter valued at approximately $2,499,000. Finally, Compagnie Lombard Odier SCmA lifted its position in shares of Oculis by 11.5% during the 2nd quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company's stock valued at $1,883,000 after acquiring an additional 10,000 shares during the period. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.